The company was evaluating the safety and efficacy of its oral treatment, bucillamine, in the study which enrolled 713 patients with mild to moderate COVID-19. Earlier in May, Revive Therapeutics said it was halting the study as it was likely that it would not meet the main goal based on the recommendation of an independent data safety monitoring board. The company said on Thursday it was pursuing certain initiatives including partnerships and government support to continue the development of bucillamine.
The securities offered under this offering document under the Listed Issuer Financing Exemption have not been, and will not be, registered under the United States Securities Act of 1933, as. | June 13, 2023
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.